* Amgen Inc., of Thousand Oaks, Calif., namedStanley Benson senior vice president of sales andmarketing.
* Athena Neurosciencs Inc., of South SanFrancisco, appointed Dennis Selkoe, Harvard UniversityMedical School professor, to the board of directors.
* Axiom Venture Partners, of Hartford, Conn.,appointed Linda Sonntag managing director of itsmedical health care investments.
* BioCryst Pharmaceuticals Inc., of Birmingham,Ala., named William Featheringill, chairman of MacessCorp., and Joseph Sherill, formerly president of R.J.Reynolds Asia Pacific, to the BioCryst board of directors.
* Biogen Inc., of Cambridge, Mass., made thefollowing appointments: Guy-Charles Fanneau de laHorie, country manager of France; Burt Adelman vicepresident of regulatory affairs; Alphonse Galdes, researchdirector of protein engineering; and Harold Price, generalmanager of the company's Research Triangle Park, N.C.,operations.
* Carrington Laboratories Inc., Irving, Texas,appointed John Phillips director of information andsupport services.
* Cell Genesys Inc., of Foster City, Calif., namedJoseph Maroun, former senior vice president of Bristol-Myers Squibb, to the board of directors.
* Corange Ltd., of Bermuda, named Gerald Mollerpresident and CEO of the Boehringer Mannheim Groupand James Lent president and CEO of the DePuy Group.
* Creative BioMolecules Inc., of Hopkinton, Mass.,named Michael Tarnow president and CEO.
* Darwin Molecular Corp., of Bothell, Wash.,appointed Gregory Abbott president and CEO.
* Derma Sciences Inc., of Old Forge, Pa., appointedthe following to its board of directors: Mary Clark,former chairman and president of Derma Sciences;Herbert Grossman, former chairman and president ofZambon Corp.; and Laurence Lane, former senior vicepresident of NovaCare Inc.
* Desmos Inc., of La Jolla, Calif., appointedCharlotte Clark vice president of business development.
* Diatech Inc., of Londonderry, N.H., appointedJohn Piper senior director of regulatory affairs.
* Epitope Inc., of Beaverton, Ore., named CharlesBergeron vice president of operations for its medicalproducts division.
* Human Genome Sciences Inc., of Rockville, Md.,named Melvin Booth president and chief operatingofficer.
* InSiteVision Inc., Alameda, Calif., named KarenChurch vice president of regulatory, quality and clinicalaffairs.
* International Murex Technologies Corp., ofAtlanta, appointed David Schaefer general manager ofmarketing and strategic planning.
* Lidak Pharmaceuticals Inc., of La Jolla, Calif.,named Gerald Yakatan vice president of drugdevelopment.
* MGI Pharma Inc., of Minneapolis, named Jon Leevice president of sales and marketing.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo.,named George Herron vice president of sales andmarketing.
* OsteoArthritis Sciences Inc., of Cambridge,Mass., named Thomas Sharpe CEO.
* Ostex International Inc., of Seattle, named thefollowing to its scientific advisory board: Robert Lindsay,president of the National Osteoporosis Foundation;Elizabeth Barrett-Connor, University of California at SanDiego School of Medicine professor; Veronic Ravnikar,University of Massachusetts Medical Center professor;Howard Judd, University of California at Los AngelesMedical Center professor; and Socrates Papapoulos,professor at the University of Leiden Medical School inThe Netherlands. In addition, Ostex appointed CorySmith director of manufacturing, Nancy Mallinakdirectory of regulatory and clinical affairs and DanielCain manager of clinical trials.
* Sequus Pharmaceuticals Inc., of Menlo Park,Calif., appointed Craig Henderson CEO and Scott Minickpresident and chief operating officer.
* TM Technologies Corp., of Toronto, appointedGregory Barnhill, managing director of Alex. Brown &Sons Inc., to the board of directors.
* Vanguard Medica Ltd., of Guildford, England,appointed Gary Acton vice president of clinicaldevelopment, Doreen Wood development projectmanager and Sally Waterman scientific operationsmanager.
(c) 1997 American Health Consultants. All rights reserved.